CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a Phase 1/1b open‐label, dose escalation and dose expansion study of CPI‐006, a humanized monoclonal antibody (mAb) targeting the CD73 cell‐surface ectonucleotidase in adult subjects with select advanced cancers. CPI‐006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti‐PD1 antibody), and in combination with ciforadenant and pembrolizumab.
Epistemonikos ID: a931e8d1cf9fa8d204557a48c972cd86034d318a
First added on: May 21, 2024